Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

41.83 -0.43 (-1.02%)
Streaming Delayed Price Updated: 10:29 AM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Oversold Stocks Ready to Bounce Back and 1 to Approach with Caution
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
2 Stocks Down 59% and 34% to Buy and Hold
Via The Motley Fool
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts
Via Benzinga
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Earnings Scheduled For February 19, 2025
Via Benzinga
Forecasting The Future: 19 Analyst Projections For Exact Sciences
Via Benzinga
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
Exposures Political
2 Small-Cap Stocks on Our Watchlist and 1 to Ignore
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
1 Healthcare Stock on Our Watchlist and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Stock Under $50 to Target This Week and 2 to Turn Down
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts
Via Benzinga
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among... 
Via Stocktwits
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Natera (NTRA) Q4 Earnings: What To Expect
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials. 
Via Benzinga
Why Exact Sciences (EXAS) Shares Are Trading Lower Today
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened... 
Via StockStory
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session. 
Via Benzinga
Exact Sciences (EXAS) Q4 2024 Earnings Call Transcript
EXAS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exact Sciences Stock Slides On Q4 Earnings: The Details
Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here's a look at the key details from the quarter. 
Via Benzinga
Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s... 
Via StockStory
Trump Calls For More Tariffs, Federal Reserve Minutes On Deck: What's Driving Markets Wednesday?
All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors. 
Via Benzinga
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
The company is working to expand the uses and reimbursement for its blood-based tests for cancer. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.